Dec 02, 2008 at 01:03 AM
Company Home
Home arrow China Pharma News arrow AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics
Home
Advanced Search
China Biotech News
China Pharma News
China Chemical News
China Companies
Web Homepage
Statistics
Visitors: 223586
Who's Online
We have 22 guests online
AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics
Written by PRNewswire   
Feb 11, 2008 at 04:23 AM

Gross Sales Per Each Location Could Exceed $400,000
 
TUSTIN, Calif., Jan. 25 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company that, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. It today announced that more than 100 individual owners of existing health spa centers in China have signed strategic cooperation agreements with JJB, a Jade subsidiary.

The agreements allow JJB to re-brand the locations as JPGreen anti-aging & spa clinics. JJB is the exclusive supplier of its anti-aging product "Goodnak." The agreements follow a January meeting at the Beijing Diaoyutai State Guesthouse that attracted approximately 200 health spa center owners who want to cooperate with JJB in order to expand the JPGreen centers.

Frank Zhang, Managing Director of Jade, stated that "these new strategic cooperation agreements will allow JJB to increase the sales of the expanding family of Goodnak anti-aging injections, capsules, creams and spray products into the China market during 2008. Each new clinic location is anticipated to annually contribute $400,000 to $700,000 in gross sales per location."

Mr. Gary Dreher, CEO of AMDL noted that "these new regional Chinese strategic cooperation relationships are significant achievements and improves Jade's ability to grow its sales in 2008 and beyond."

About Jade Pharmaceutical: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice ('CGMP') standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

     Contact: AMDL, Inc.
     Gary L. Dreher
     President & CEO
     (714) 505-4460
 

<Previous   Next>
Latest News